Deciphering Mechanisms of ARIA & How to Mitigate it to Bolster the Potential of Anti-Aβ Antibody Therapies

ARIA-related adverse events continue to pose a significant barrier to the long-term safety and efficacy of anti amyloid beta antibody therapeutics. However, the underlying mechanisms driving ARIA‑E and ARIA‑H remain poorly defined, reflecting the complex interplay between amyloid clearance, vascular injury, inflammation, and BBB integrity. Exchange insights with leading neurodegeneration experts to advance strategies for mitigating ARIA, exploring key concepts such as:

• From plaque clearance and vascular binding to downstream vascular failure, what is the dominating initiating event?
• What specific biological pathway causes BBB permeability to increase?
• Is ARIA primarily inflammatory, vascular, or a hybrid process?
• Why is ARIA more serious in certain populations like APOE ε 4 carriers and how can this be dealt with?